Skip to NavigationSkip to content

Roche's Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma

Published on 16/12/19 at 04:48pm

Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when combined with Cotellic (cobimetinib) and Zelboraf (vemurafenib), met its primary endpoint in the treatment of previously untreated BRAF V600 mutation-positive advanced melanoma.

While specifics of the findings were not revealed, Roche confirmed that the combo generated a “significant and clinically meaningful” improvement in progression-free survival (PFS) compared to placebo plus Cotellic and Zelboraf.

The company also confirmed that the full details of the findings would be presented at an upcoming medical meeting, and that they will also help form the basis for regulatory submissions with the FDA and EMA.

“By combining a cancer immunotherapy with targeted therapies, we hope to offer a new approach that improves outcomes for people with advanced, BRAF-mutant melanoma," commented Dr Levi Garraway, Chief Medical Officer and Head of Global Product Development at Roche. "We look forward to discussing the results with health authorities around the world.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches